Visão geral da empresa
A clinical-stage biopharmaceutical enterprise, Neumora Therapeutics, Inc. is dedicated to the development of therapeutic interventions targeting brain diseases, neuropsychiatric disorders, and neurodegenerative conditions within the United States market. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, positioning itself to capitalize on the high-growth potential of novel drug candidates like navacaprant (NMRA-140). As of the latest reported data, the enterprise possesses a market capitalization of $364.08M, though specific annual revenue figures and employee counts are not currently disclosed in the available financial records. These valuation metrics, particularly a market cap hovering in the mid-hundreds of millions, suggest a company in an early-stage development phase where capital allocation focuses heavily on research and clinical trials rather than established sales volumes or large-scale operational headcount.
Saúde financeira
The financial performance of Neumora Therapeutics is characterized by significant negative operating metrics, with Net Income (TTM) recorded at $-236,928,000 and EBITDA standing at $-235,948,000. The substantial gap between N/A revenue figures and these heavy net losses reveals a cost structure dominated by R&D expenditures and clinical trial costs typical of pre-commercial biotechnology firms. The company reported Free Cash Flow of $-115,712,376, indicating a continuous outflow of cash required to sustain operations and advance development pipelines without current product commercialization. Margins across the board reflect this pre-revenue status, with Gross Margin, Operating Margin, and Profit Margin all registered at 0.0%, indicating that the company has not yet generated profitable sales to cover its direct costs or operational expenses. To fund these activities, the company maintains a Cash position of $182.53M against total Debt of $55.01M, resulting in a Debt to Equity ratio of 52.96 which highlights a highly leveraged balance sheet relative to equity but a net cash position in absolute terms. Liquidity is robust in the short term, evidenced by a Current Ratio of 5.87, which suggests the company holds more than five times the current assets necessary to cover its immediate liabilities. However, the Return on Equity stands at -121.2% and Return on Assets at -58.1%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a common but financially demanding situation for clinical-stage entities.
Avaliação de valorização
Valuation multiples for Neumora Therapeutics present a mixed picture due to the lack of earnings and sales data, with the P/E Ratio (TTM) listed as N/A and the Forward P/E calculated at -2.16. The negative forward P/E implies that the market anticipates a return to profitability or a turnaround in earnings trajectory in the future, although current trailing earnings remain deeply negative. The Price to Book ratio is set at 3.36, suggesting the market values the company at a premium over its tangible book value, likely reflecting the intangible value of its intellectual property and drug candidates. Alternative valuation metrics such as Price to Sales, which is N/A, and EV/EBITDA at -1.00, indicate that traditional sales-based or cash-flow-based valuation models are not yet applicable due to the absence of positive sales or earnings. Price volatility is significant, with the 52-week high recorded at $3.65 and the 52-week low at $0.61; without the current price explicitly listed in the source data, the range indicates a wide trading band typical of speculative biotech stocks. The Beta of 3.12 further contextualizes this risk, showing that the stock's price volatility is more than three times that of the broader market, making it highly sensitive to shifts in investor sentiment regarding clinical trial outcomes.
Growth & Income
Growth metrics for Neumora Therapeutics are currently unquantifiable in terms of percentage rates, as Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A. In the absence of historical positive earnings, the concept of earnings growing faster or slower than revenue does not yet apply, as the company is in a development phase where absolute growth in clinical milestones is the primary driver rather than percentage-based financial expansion. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which is consistent with its strategy of reinvesting all available capital and cash reserves into advancing its drug candidates rather than distributing income to shareholders. Consequently, the overall growth and income profile for Neumora Therapeutics is defined entirely by the potential future commercialization of its pipeline, with current financial resources being deployed to bridge the gap between clinical development and market entry rather than generating immediate income streams.